2/18/2024 0 Comments Nurtec copay card 2022![]() ![]() And that’s a profile we saw in Nurtec® ODT. Migraine patients want their migraines to go away and don’t want new problems. When you look at the older triptans that are used here, they’re plagued with side effects. We believed Nurtec® ODT was going to be a product that not only had more efficacy, but really it changed the paradigm on the safety front. We viewed that as a big opportunity, and that’s really what got us to focus on in-license strategies, including Nurtec® ODT. Many companies had decided that they were going to exit neuroscience, which created a unique opportunity for us at Biohaven because these are some of the worst disorders that face society, yet our largest companies were leaving the area. Most of pharma was focused on immuno-oncology. Vlad Coric: When we go back to the decision to license Nurtec® ODT, you have to appreciate what was going on in the greater pharma field at the time. What were your expectations for the product and the market opportunity, and then what actually happened? What’d you get wrong? And that can be both good and bad. Take us back to your original decision to license rimegepant out of BMS. Sixth Street: Vlad, thanks for doing this and congratulations on the Pfizer acquisition. Learn more about Sixth Street Healthcare and Life Sciences In this conversation, Sixth Street’s Healthcare and Life Sciences team talks with Vlad Coric, MD about the firm’s capital strategy, the broader biotech market, and what’s next for the company with Pfizer. The transaction subsequently closed in October of 2022. In May 2022, Biohaven announced that Pfizer was acquiring the company for $11.6 billion. Sixth Street would later upsize the financing to a total of $750 million. Sixth Street provided Biohaven, a publicly listed company, with $500 million in non-dilutive financing as it brought Nurtec® ODT to market against incumbent big pharma migraine treatments. The company is best known for Nurtec® ODT (rimegepant 75 mg), which received FDA approval in February 2020 as the first orally disintegrating CGRP antagonist for the acute treatment of migraine.īiohaven’s relationship with Sixth Street dates to early 2020, when the company began seeking capital to finance the commercialization of Nurtec® ODT following FDA approval. We sat down with Vlad Coric, CEO of Biohaven, for a behind-the-scenes look at how Sixth Street’s solutions helped bring a novel therapy to migraine patients and what’s next for the company after its acquisition by Pfizer.īiohaven (NYSE: BHVN) is a commercial-stage biopharmaceutical company with a portfolio of late-stage product candidates targeting neurological and neuropsychiatric diseases, including rare disorders.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |